<DOC>
	<DOCNO>NCT00335270</DOCNO>
	<brief_summary>The purpose study evaluate antiretroviral efficacy , safety , tolerability fos-amprenavir boost either two dos ritonavir ( RTV ) administer combination ABC/3TC ( abacavir/lamivudine , Epzicom® ) FDC ( fix dose combination ) once-daily regimen 96 week ART-naïve , HIV-infected adult</brief_summary>
	<brief_title>A Randomized , Prospective Study Efficacy , Safety Tolerability Two Doses GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination</brief_title>
	<detailed_description>The optimal long-term management HIV-1 infection necessitate chronic use highly effective , well-tolerated antiretroviral ( ARV ) combination therapy , ideally preserve future treatment option . Current preferred standard treatment HIV consist regimen compose protease inhibitor ( PI ) non-nucleoside reverse transcriptase inhibitor ( NNRTI ) plus 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) . A recent trend may contribute improve rate treatment response use regimens few pill daily dose . This study design assess two PI option consist four five pill take daily - option may also offer advantage term metabolic consequence . The primary objective multi-center , open-label , randomize , two-arm , pilot study evaluate antiretroviral efficacy , safety , tolerability ( adverse event metabolic profile ) fos-amprenavir ( fAPV ) boost either two dos ritonavir ( RTV ) administer combination ABC/3TC ( abacavir/lamivudine , Epzicom® ) FDC ( fix dose combination ) once-daily regimen 48 week ART-naïve , HIV-infected adult . Approximately 100 subject enrol 10 site United States . Subjects must &gt; 18 year age , ART-naïve ( &lt; 7 day prior therapy licensed investigational ARV drug ) plasma HIV-1 RNA &gt; 1,000 copies/mL . A CD4+ cell count &gt; 50 cells/mm3 initially required eligibility . Amendment 1 drop requirement . Subjects stratify entry accord screen plasma HIV-1 RNA level ( &lt; 100,000 copies/mL &gt; 100,000 copies/mL ) . Eligible subject randomize ( 1:1 ) one follow two treatment arm 96 week ; fAPV 1400 mg/RTV 100 mg QD plus ABC 600 mg/3TC 300 mg FDC QD ( Treatment Arm A ) fAPV 1400 mg/RTV 200 mg QD plus ABC 600 mg/3TC 300 mg FDC QD ( Treatment Arm B ) .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV1 infection Male Female 18 year age older Has plasma HIV1 RNA ( viral load ) 1,000 copies/mL screen Subject antiretroviralnaïve ( le 7 day prior therapy agent Competency Not pregnant willing use effective birth control applicable . Inability comply due preexist mental , physical , substance abuse disorder reason . Has active/acute CDC Clinical Category C event screening . Has history inflammatory bowel disease , gastrointestinal malignancy , intestinal ischemia , malabsorption gastrointestinal dysfunction . Females pregnant breastfeeding . Has serious medical condition , diabetes , congestive heart failure , cardiomyopathy cardiac dysfunction , opinion investigator would compromise safety subject . Has ongoing clinically relevant pancreatitis clinically relevant hepatitis screening . Requires treatment foscarnet , hydroxyurea agent document activity HIV1 vitro within 28 day study drug administration . Has acute laboratory abnormality screening , opinion investigator , preclude subject 's participation study . Any Grade 4 laboratory result would exclude subject study participation . Has require treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day prior screen , anticipated need treatment within study period . Requires treatment immunomodulating agent ( systemic corticosteroid , interleukin , vaccine , interferon ) within 28 day prior screen subject receive HIV1 immunotherapeutic vaccine within 90 day prior screen . Has history allergy study drug excipients therein . Is enrolled plan enroll one investigational drug protocol , may impact HIV RNA suppression . Requiring treatment pharmacological agent diabetes , elevate triglycerides/cholesterol . Has AST ALT &gt; 5 time upper limit normal ( ULN ) . Has estimate creatinine clearance &lt; 50 mL/min via CockcroftGault method Subject require treatment follow medication within 28 day prior study drug administration , anticipate need study : amiodarone , astemizole , bepridil , cisapride , dihydroergotamine , ergonovine , ergotamine , flecainide , halofantrine , lidocaine , lovastatin , methylergonovine , midazolam , pimozide , propafenone , quinidine , simvastatin , terfenadine , triazolam , carbamazepine , dexamethasone , phenobarbital , phenytoin , primidone , rifampin , St. John 's Wort ( hypericum perforatum )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>HIV Type 1</keyword>
</DOC>